Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer

Breast Cancer Research

Volumn 14, Issue 2, 2012, Pages

  Su, Fuqin ^a,b   Ren, Fangli ^a   Rong, Yu ^a   Wang, Yangmeng ^a   Geng, Yongtao ^c   Wang, Yinyin ^a   Feng, Mengyao ^a   Ju, Yanfang ^c   Li, Yi ^d   Zhao, Zhizhuang J ^e   Meng, Kun ^f   Chang, Zhijie ^a  

^a Tsinghua University   (China)

^b Qiqihar Medical Collage ^*  (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d PEKING UNIVERSITY   (China)

^e UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^f Beijing Cell Technology Inc   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE MEG2; STAT3 PROTEIN; UNCLASSIFIED DRUG; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE; PTPN9 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE; TYROSINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TISSUE; CONTROLLED STUDY; CYTOPLASM; DEPHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; ANIMAL; BAGG ALBINO MOUSE; BREAST TUMOR; CELL PROLIFERATION; DRUG SCREENING; FEMALE; GENE INACTIVATION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE KNOCKOUT TECHNIQUES; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR SEQUENCE DATA; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TYROSINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862798329     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3134     Document Type: Article

References (34)

1. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000, 19:2548-2556. 10.1038/sj.onc.1203551, 10851053.
2. Wei L, Laurence A, O'Shea JJ. New insights into the roles of Stat5a/b and Stat3 in T cell development and differentiation. Semin Cell Dev Biol 2008, 19:394-400. 10.1016/j.semcdb.2008.07.011, 2657870, 18708155.
3. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we?. Expert Opin Investig Drugs 2009, 18:45-56. 10.1517/13543780802565791, 2610472, 19053881.
4. Frank DA. STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett 2007, 251:199-210. 10.1016/j.canlet.2006.10.017, 17129668.
5. Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. New and old functions of STAT3: a pivotal target for individualized treatment of cancer. Cell Cycle 2005, 4:1131-1133. 10.4161/cc.4.9.1985, 16082218.
6. den Hertog J, Ostman A, Bohmer FD. Protein tyrosine phosphatases: regulatory mechanisms. FEBS J 2008, 275:831-847. 10.1111/j.1742-4658.2008.06247.x, 18298791.
7. Aoki N, Matsuda T. A nuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway: dephosphorylation and deactivation of signal transducer and activator of transcription 5a and 5b by TC-PTP in nucleus. Mol Endocrinol 2002, 16:58-69. 10.1210/me.16.1.58, 11773439.
8. Johnson KJ, Peck AR, Liu C, Tran TH, Utama FE, Sjolund AB, Schaber JD, Witkiewicz AK, Rui H. PTP1B Suppresses Prolactin Activation of Stat5 in Breast Cancer Cells. Am J Pathol 2010,
9. Lu X, Malumbres R, Shields B, Jiang X, Sarosiek KA, Natkunam Y, Tiganis T, Lossos IS. PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling. Blood 2008, 112:4098-4108. 10.1182/blood-2008-03-148726, 2582009, 18716132.
10. Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ, Malki S, Alderman BM, Grail D, Hollande F, Heath JK, Ernst M. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 2002, 8:1089-1097. 10.1038/nm763, 12219085.
11. Baron M, Davignon JL. Inhibition of IFN-gamma-induced STAT1 tyrosine phosphorylation by human CMV is mediated by SHP2. J Immunol 2008, 181:5530-5536.
12. Tsai CC, Kai JI, Huang WC, Wang CY, Wang Y, Chen CL, Fang YT, Lin YS, Anderson R, Chen SH, Tsao CW, Lin CF. Glycogen synthase kinase-3beta facilitates IFN-gamma-induced STAT1 activation by regulating Src homology-2 domain-containing phosphatase 2. J Immunol 2009, 183:856-864. 10.4049/jimmunol.0804033, 19542364.
13. ten Hoeve J, de Jesus Ibarra-Sanchez M, Fu Y, Zhu W, Tremblay M, David M, Shuai K. Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 2002, 22:5662-5668. 10.1128/MCB.22.16.5662-5668.2002, 133976, 12138178.
14. Meyer T, Hendry L, Begitt A, John S, Vinkemeier U. A single residue modulates tyrosine dephosphorylation, oligomerization, and nuclear accumulation of stat transcription factors. J Biol Chem 2004, 279:18998-19007. 10.1074/jbc.M400766200, 15010467.
15. Chughtai N, Schimchowitsch S, Lebrun JJ, Ali S. Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells. J Biol Chem 2002, 277:31107-31114. 10.1074/jbc.M200156200, 12060651.
16. Lessard L, Stuible M, Tremblay ML. The two faces of PTP1B in cancer. Biochim Biophys Acta 2010, 1804:613-619.
17. Yi T, Lindner D. The role and target potential of protein tyrosine phosphatases in cancer. Curr Oncol Rep 2008, 10:114-121. 10.1007/s11912-008-0019-6, 18377824.
18. Cho CY, Koo SH, Wang Y, Callaway S, Hedrick S, Mak PA, Orth AP, Peters EC, Saez E, Montminy M, Schultz PG, Chanda SK. Identification of the tyrosine phosphatase PTP-MEG2 as an antagonist of hepatic insulin signaling. Cell Metab 2006, 3:367-378. 10.1016/j.cmet.2006.03.006, 16679294.
19. Chen M, Sun JP, Liu J, Yu X. Research progress of several protein tyrosine phosphatases in diabetes. Sheng Li Xue Bao 2010, 62:179-189.
20. Yuan T, Wang Y, Zhao ZJ, Gu H. Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells. J Biol Chem 2010, 285:14861-14870. 10.1074/jbc.M109.099879, 2865303, 20335174.
21. Huynh H, Bottini N, Williams S, Cherepanov V, Musumeci L, Saito K, Bruckner S, Vachon E, Wang X, Kruger J, Chow CW, Pellecchia M, Monosov E, Greer PA, Trimble W, Downey GP, Mustelin T. Control of vesicle fusion by a tyrosine phosphatase. Nat Cell Biol 2004, 6:831-839. 10.1038/ncb1164, 15322554.
22. Wang Y, Vachon E, Zhang J, Cherepanov V, Kruger J, Li J, Saito K, Shannon P, Bottini N, Huynh H, Ni H, Yang H, McKerlie C, Quaggin S, Zhao ZJ, Marsden PA, Mustelin T, Siminovitch KA, Downey GP. Tyrosine phosphatase MEG2 modulates murine development and platelet and lymphocyte activation through secretory vesicle function. J Exp Med 2005, 202:1587-1597. 10.1084/jem.20051108, 2213338, 16330817.
23. Xu MJ, Sui X, Zhao R, Dai C, Krantz SB, Zhao ZJ. PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells. Blood 2003, 102:4354-4360. 10.1182/blood-2003-04-1308, 12920026.
24. Furth PA, Nakles RE, Millman S, Diaz-Cruz ES, Cabrera MC. Signal transducer and activator of transcription 5 as a key signaling pathway in normal mammary gland developmental biology and breast cancer. Breast Cancer Res 2011, 13:220. 10.1186/bcr2921, 22018398.
25. Zhang T, Seow KT, Ong CT, Cao X. Interdomain interaction of Stat3 regulates its Src homology 2 domain-mediated receptor binding activity. J Biol Chem 2002, 277:17556-17563. 10.1074/jbc.M105525200, 11872739.
26. Wang F, Zhang H, Zhang X, Wang Y, Ren F, Zhai Y, Chang Z. Varp interacts with Rab38 and functions as its potential effector. Biochem Biophys Res Commun 2008, 372:162-167. 10.1016/j.bbrc.2008.05.017, 18477474.
27. Qi Y, Zhao R, Cao H, Sui X, Krantz SB, Zhao ZJ. Purification and characterization of protein tyrosine phosphatase PTP-MEG2. J Cell Biochem 2002, 86:79-89. 10.1002/jcb.10195, 12112018.
28. Zhou L, He XD, Cui QC, Zhou WX, Qu Q, Zhou RL, Rui JA, Yu JC. Expression of LAPTM4B-35: A novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma. Cancer Lett 2008, 264:209-217. 10.1016/j.canlet.2008.01.025, 18334282.
29. Costantino L, Barlocco D. STAT 3 as a target for cancer drug discovery. Curr Med Chem 2008, 15:834-843. 10.2174/092986708783955464, 18473793.
30. Julien SG, Dube N, Hardy S, Tremblay ML. Inside the human cancer tyrosine phosphatome. Nat Rev Cancer 2010, 11:35-49.
31. Sun T, Aceto N, Meerbrey KL, Kessler JD, Zhou C, Migliaccio I, Nguyen DX, Pavlova NN, Botero M, Huang J, Bernardi RJ, Schmitt E, Hu G, Li MZ, Dephoure N, Gygi SP, Rao M, Creighton CJ, Hilsenbeck SG, Shaw CA, Muzny D, Gibbs RA, Wheeler DA, Osborne CK, Schiff R, Bentires-Alj M, Elledge SJ, Westbrook TF. Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase. Cell 2011, 144:703-718. 10.1016/j.cell.2011.02.003, 21376233.
32. Fridberg M, Kjellstrom S, Anagnostaki L, Skogvall I, Mustelin T, Wiebe T, Persson JL, Dictor M, Wingren AG. Immunohistochemical analyses of phosphatases in childhood B-cell lymphoma: lower expression of PTEN and HePTP and higher number of positive cells for nuclear SHP2 in B-cell lymphoma cases compared to controls. Pediatr Hematol Oncol 2008, 25:528-540. 10.1080/08880010802237054, 18728972.
33. Glondu-Lassis M, Dromard M, Lacroix-Triki M, Nirde P, Puech C, Knani D, Chalbos D, Freiss G. PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase. Cancer Res 2010, 70:5116-5126. 10.1158/0008-5472.CAN-09-4368, 3132424, 20501847.
34. Dromard M, Bompard G, Glondu-Lassis M, Puech C, Chalbos D, Freiss G. The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation. Cancer Res 2007, 67:6806-6813. 10.1158/0008-5472.CAN-07-0513, 17638892.